Neuropathic pain is a debilitating condition affecting millions of people worldwide. A new study investigates mechanisms of neuropathic pain initiation and identifies a promising therapeutic currently used for acute respiratory distress syndrome that may also limit acute neuropathic pain.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
International Association for the Study of Pain. Epidemiology of neuropathic pain: how common is neuropathic pain, and what is its impact? (IASP, 2015).
Baron, R., Binder, A. & Wasner, G. Lancet Neurol. 9, 807–819 (2010).
Finnerup, N.B. et al. Lancet 14, 162–173 (2015).
Cohen, S.P. & Mao, J. Br. Med. J. 348, f7656 (2014).
Vicuña, L. et al. Nat. Med. 21, 518–523 (2015).
Aikawa, N. & Kawasaki, Y. Ther. Clin. Risk Manag. 10, 621–629 (2014).
Zeiher, B.G. et al. Crit. Care Med. 32, 1695–1702 (2004).
Finnerup, N.B. et al. Eur. J. Pain 17, 953–956 (2013).
Berufsverband der Ärtze und Psychologischen Psychotherapeutan in der Schmerz- und Palliativmedizin in Deutschland (BVSD). Weißbuch Schmerzmedizin [White Book on Pain Medicine] (BVSD, 2012).
Von Hehn, C.A., Baron, R. & Woolf, C.J. Neuron 73, 638–652 (2012).
The authors declare no competing financial interests.
About this article
Cite this article
Weyer, A., Stucky, C. Repurposing a leukocyte elastase inhibitor for neuropathic pain. Nat Med 21, 429–430 (2015). https://doi.org/10.1038/nm.3861